カテゴリー： P&S Market Research, 世界, 消費財/食品

臨床試験用品の世界市場：産業分析・成長予測（～2030）

P&S Market Researchが発行した調査報告書（PS24MAR041）◆商品コード：PS24MAR041
◆発行会社（リサーチ会社）：P&S Market Research
◆発行日：2023年11月
◆ページ数：260
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後3営業日）
◆調査対象地域：グローバル
◆産業分野：消費財
◆販売価格オプション（消費税別）
Single UserUSD4,900 ⇒換算￥744,800見積依頼/購入/質問フォーム
Group UserUSD6,400 ⇒換算￥972,800見積依頼/購入/質問フォーム
Enterprise UserUSD8,400 ⇒換算￥1,276,800見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

臨床試験用品市場は、2023年には4,001.1百万米ドルであったが、2030年には7,763.9百万米ドルに達し、この10年末までに年平均成長率10.1％で拡大すると予測されます。市場の成長を後押ししている主な要因は、個別化医療など最先端の治療に対する需要が雪だるま式に増加していること、バイオファーマや製薬会社の研究開発費が増加していること、疾病の発生が増加していることであり、これらが根本的に新薬の拡大をもたらしています。
近年、臨床試験の数は大幅に増加しています。2023年には、約0.4百万件の臨床試験が米国政府に記録されました。臨床試験の増加は、必要不可欠な物資の需要に比例しています。研究開発費の増加は、革新的な医薬品の拡大プロセスを後押しし、実施された臨床試験の数を雪だるま式に増やしています。
さらに、日本は世界第2位の製薬市場であり、医薬品売上高の約12％を占めています。そのため、研究者が医薬品や医療機器の治験を数多く実施していることから、臨床試験用品業界の売上は急速に伸びています。さらに、日本の人口は約1億2,500万人と多く、最先端の治療薬が数多く求められています。

第3相試験カテゴリーは、2023年には約40％のシェアで業界をリードしています。これは、この段階の臨床試験の価格が高いためです。フェーズIIIは、フェーズ1やフェーズ2と比較して、より多くの患者集団を必要とし、これがフレーズIII試験の高額な費用の主な理由の一つです。
さらに、第1相臨床試験カテゴリーは、臨床試験用品市場で最も急速に成長します。これは、製薬企業の研究開発パイプラインが増加し、初期段階の試験数が増加した結果です。
北米は2023年に45%のシェアを占め、業界をリードしています。これは、改良されたより安全な医薬品の成長に重点が置かれ、臨床試験の回数が増加しているためです。あらゆる疾患の増加、製薬会社やバイオテクノロジー企業の増加、医薬品の研究開発に対する政府の好意的な法規制は、基本的に治験薬の臨床試験中に必要とされる数多くの供給品に対する要求の増加をもたらしています。
APACは、インド、中国、オーストラリアにおける研究開発パイプラインの拡大が原動力となり、今後数年間で最も急成長を遂げるでしょう。基本的に、臨床試験に貢献する多くの患者を確保できることが、最終的に薬剤成長の需要を高めています。さらに最近、臨床段階の研究を行う受託研究機関の数が増加しています。
世界中で臨床試験の数が増加しているため、臨床試験用品の需要が増加しています。

臨床試験用品市場の主要企業は以下の通りです。
Thermo Fisher Scientific Inc.
Marken
Catalent Inc.
Parexel International
Almac Group Limited
Biocair International Limited
Sharp Services LLC
Movianto International BV
PCI Pharma Services
Eurofins Scientific

第1章．調査範囲
第2章．調査方法
第3章．エグゼクティブサマリー
第4章．市場指標
第5章．産業動向
第6章．世界市場
第7章．北米市場
第8章．ヨーロッパ市場
第9章．アジア太平洋市場
第10章．中南米市場
第11章．中東/アフリカ市場
第12章．アメリカ市場
第13章．カナダ市場
第14章．ドイツ市場
第15章．フランス市場
第16章．イギリス市場
第17章．イタリア市場
第18章．スペイン市場
第19章．日本市場
第20章．中国市場
第21章．インド市場
第22章．オーストラリア市場
第23章．韓国市場
第24章．ブラジル市場
第25章．メキシコ市場
第26章．サウジアラビア市場
第27章．南アフリカ市場
第28章．中東市場
第29章．競争状況
第30章．企業情報
第31章．付録

❖ レポートの目次 ❖

Chapter 1. Research Scope

1.1. Research Objectives

1.2. Market Definition

1.3. Analysis Period

1.4. Market Size Breakdown by Segments

1.4.1. Market size breakdown, by phase

1.4.2. Market size breakdown, by therapeutic application

1.4.3. Market size breakdown, by service

1.4.4. Market size breakdown, by end user

1.4.5. Market size breakdown, by region

1.4.6. Market size breakdown, by country

1.5. Market Data Reporting Unit

1.5.1. Volume

1.5.2. Value

1.6. Key Stakeholders

Chapter 2. Research Methodology

2.1. Secondary Research

2.1.1. Paid

2.1.2. Unpaid

2.1.3. P&S Intelligence database

2.2. Primary Research

2.3. Market Size Estimation

2.4. Data Triangulation

2.5. Currency Conversion Rates

2.6. Assumptions for the Study

2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

5.1. Market Dynamics

5.1.1. Trends

5.1.2. Drivers

5.1.3. Restraints/challenges

5.1.4. Impact analysis of drivers/restraints

5.2. Impact of COVID-19

5.3. Porter’s Five Forces Analysis

5.3.1. Bargaining power of buyers

5.3.2. Bargaining power of suppliers

5.3.3. Threat of new entrants

5.3.4. Intensity of rivalry

5.3.5. Threat of substitutes

Chapter 6. Global Market

6.1. Overview

6.2. Market Volume, by Phase (2017–2030)

6.3. Market Revenue, by Phase (2017–2030)

6.4. Market Volume, by Therapeutic Application (2017–2030)

6.5. Market Revenue, by Therapeutic Application (2017–2030)

6.6. Market Volume, by Service (2017–2030)

6.7. Market Revenue, by Service (2017–2030)

6.8. Market Volume, by End User (2017–2030)

6.9. Market Revenue, by End User (2017–2030)

6.10. Market Volume, by Region (2017–2030)

6.11. Market Revenue, by Region (2017–2030)

Chapter 7. North America Market

7.1. Overview

7.2. Market Volume, by Phase (2017–2030)

7.3. Market Revenue, by Phase (2017–2030)

7.4. Market Volume, by Therapeutic Application (2017–2030)

7.5. Market Revenue, by Therapeutic Application (2017–2030)

7.6. Market Volume, by Service (2017–2030)

7.7. Market Revenue, by Service (2017–2030)

7.8. Market Volume, by End User (2017–2030)

7.9. Market Revenue, by End User (2017–2030)

7.10. Market Volume, by Country (2017–2030)

7.11. Market Revenue, by Country (2017–2030)

Chapter 8. Europe Market

8.1. Overview

8.2. Market Volume, by Phase (2017–2030)

8.3. Market Revenue, by Phase (2017–2030)

8.4. Market Volume, by Therapeutic Application (2017–2030)

8.5. Market Revenue, by Therapeutic Application (2017–2030)

8.6. Market Volume, by Service (2017–2030)

8.7. Market Revenue, by Service (2017–2030)

8.8. Market Volume, by End User (2017–2030)

8.9. Market Revenue, by End User (2017–2030)

8.10. Market Volume, by Country (2017–2030)

8.11. Market Revenue, by Country (2017–2030)

Chapter 9. APAC Market

9.1. Overview

9.2. Market Volume, by Phase (2017–2030)

9.3. Market Revenue, by Phase (2017–2030)

9.4. Market Volume, by Therapeutic Application (2017–2030)

9.5. Market Revenue, by Therapeutic Application (2017–2030)

9.6. Market Volume, by Service (2017–2030)

9.7. Market Revenue, by Service (2017–2030)

9.8. Market Volume, by End User (2017–2030)

9.9. Market Revenue, by End User (2017–2030)

9.10. Market Volume, by Country (2017–2030)

9.11. Market Revenue, by Country (2017–2030)

Chapter 10. LATAM Market

10.1. Overview

10.2. Market Volume, by Phase (2017–2030)

10.3. Market Revenue, by Phase (2017–2030)

10.4. Market Volume, by Therapeutic Application (2017–2030)

10.5. Market Revenue, by Therapeutic Application (2017–2030)

10.6. Market Volume, by Service (2017–2030)

10.7. Market Revenue, by Service (2017–2030)

10.8. Market Volume, by End User (2017–2030)

10.9. Market Revenue, by End User (2017–2030)

10.10. Market Volume, by Country (2017–2030)

10.11. Market Revenue, by Country (2017–2030)

Chapter 11. MEA Market

11.1. Overview

11.2. Market Volume, by Phase (2017–2030)

11.3. Market Revenue, by Phase (2017–2030)

11.4. Market Volume, by Therapeutic Application (2017–2030)

11.5. Market Revenue, by Therapeutic Application (2017–2030)

11.6. Market Volume, by Service (2017–2030)

11.7. Market Revenue, by Service (2017–2030)

11.8. Market Volume, by End User (2017–2030)

11.9. Market Revenue, by End User (2017–2030)

11.10. Market Volume, by Country (2017–2030)

11.11. Market Revenue, by Country (2017–2030)

Chapter 12. U.S. Market

12.1. Overview

12.2. Market Volume, by Phase (2017–2030)

12.3. Market Revenue, by Phase (2017–2030)

12.4. Market Volume, by Therapeutic Application (2017–2030)

12.5. Market Revenue, by Therapeutic Application (2017–2030)

12.6. Market Volume, by Service (2017–2030)

12.7. Market Revenue, by Service (2017–2030)

12.8. Market Volume, by End User (2017–2030)

12.9. Market Revenue, by End User (2017–2030)

Chapter 13. Canada Market

13.1. Overview

13.2. Market Volume, by Phase (2017–2030)

13.3. Market Revenue, by Phase (2017–2030)

13.4. Market Volume, by Therapeutic Application (2017–2030)

13.5. Market Revenue, by Therapeutic Application (2017–2030)

13.6. Market Volume, by Service (2017–2030)

13.7. Market Revenue, by Service (2017–2030)

13.8. Market Volume, by End User (2017–2030)

13.9. Market Revenue, by End User (2017–2030)

Chapter 14. Germany Market

14.1. Overview

14.2. Market Volume, by Phase (2017–2030)

14.3. Market Revenue, by Phase (2017–2030)

14.4. Market Volume, by Therapeutic Application (2017–2030)

14.5. Market Revenue, by Therapeutic Application (2017–2030)

14.6. Market Volume, by Service (2017–2030)

14.7. Market Revenue, by Service (2017–2030)

14.8. Market Volume, by End User (2017–2030)

14.9. Market Revenue, by End User (2017–2030)

Chapter 15. France Market

15.1. Overview

15.2. Market Volume, by Phase (2017–2030)

15.3. Market Revenue, by Phase (2017–2030)

15.4. Market Volume, by Therapeutic Application (2017–2030)

15.5. Market Revenue, by Therapeutic Application (2017–2030)

15.6. Market Volume, by Service (2017–2030)

15.7. Market Revenue, by Service (2017–2030)

15.8. Market Volume, by End User (2017–2030)

15.9. Market Revenue, by End User (2017–2030)

Chapter 16. U.K. Market

16.1. Overview

16.2. Market Volume, by Phase (2017–2030)

16.3. Market Revenue, by Phase (2017–2030)

16.4. Market Volume, by Therapeutic Application (2017–2030)

16.5. Market Revenue, by Therapeutic Application (2017–2030)

16.6. Market Volume, by Service (2017–2030)

16.7. Market Revenue, by Service (2017–2030)

16.8. Market Volume, by End User (2017–2030)

16.9. Market Revenue, by End User (2017–2030)

Chapter 17. Italy Market

17.1. Overview

17.2. Market Volume, by Phase (2017–2030)

17.3. Market Revenue, by Phase (2017–2030)

17.4. Market Volume, by Therapeutic Application (2017–2030)

17.5. Market Revenue, by Therapeutic Application (2017–2030)

17.6. Market Volume, by Service (2017–2030)

17.7. Market Revenue, by Service (2017–2030)

17.8. Market Volume, by End User (2017–2030)

17.9. Market Revenue, by End User (2017–2030)

Chapter 18. Spain Market

18.1. Overview

18.2. Market Volume, by Phase (2017–2030)

18.3. Market Revenue, by Phase (2017–2030)

18.4. Market Volume, by Therapeutic Application (2017–2030)

18.5. Market Revenue, by Therapeutic Application (2017–2030)

18.6. Market Volume, by Service (2017–2030)

18.7. Market Revenue, by Service (2017–2030)

18.8. Market Volume, by End User (2017–2030)

18.9. Market Revenue, by End User (2017–2030)

Chapter 19. Japan Market

19.1. Overview

19.2. Market Volume, by Phase (2017–2030)

19.3. Market Revenue, by Phase (2017–2030)

19.4. Market Volume, by Therapeutic Application (2017–2030)

19.5. Market Revenue, by Therapeutic Application (2017–2030)

19.6. Market Volume, by Service (2017–2030)

19.7. Market Revenue, by Service (2017–2030)

19.8. Market Volume, by End User (2017–2030)

19.9. Market Revenue, by End User (2017–2030)

Chapter 20. China Market

20.1. Overview

20.2. Market Volume, by Phase (2017–2030)

20.3. Market Revenue, by Phase (2017–2030)

20.4. Market Volume, by Therapeutic Application (2017–2030)

20.5. Market Revenue, by Therapeutic Application (2017–2030)

20.6. Market Volume, by Service (2017–2030)

20.7. Market Revenue, by Service (2017–2030)

20.8. Market Volume, by End User (2017–2030)

20.9. Market Revenue, by End User (2017–2030)

Chapter 21. India Market

21.1. Overview

21.2. Market Volume, by Phase (2017–2030)

21.3. Market Revenue, by Phase (2017–2030)

21.4. Market Volume, by Therapeutic Application (2017–2030)

21.5. Market Revenue, by Therapeutic Application (2017–2030)

21.6. Market Volume, by Service (2017–2030)

21.7. Market Revenue, by Service (2017–2030)

21.8. Market Volume, by End User (2017–2030)

21.9. Market Revenue, by End User (2017–2030)

Chapter 22. Australia Market

22.1. Overview

22.2. Market Volume, by Phase (2017–2030)

22.3. Market Revenue, by Phase (2017–2030)

22.4. Market Volume, by Therapeutic Application (2017–2030)

22.5. Market Revenue, by Therapeutic Application (2017–2030)

22.6. Market Volume, by Service (2017–2030)

22.7. Market Revenue, by Service (2017–2030)

22.8. Market Volume, by End User (2017–2030)

22.9. Market Revenue, by End User (2017–2030)

Chapter 23. South Korea Market

23.1. Overview

23.2. Market Volume, by Phase (2017–2030)

23.3. Market Revenue, by Phase (2017–2030)

23.4. Market Volume, by Therapeutic Application (2017–2030)

23.5. Market Revenue, by Therapeutic Application (2017–2030)

23.6. Market Volume, by Service (2017–2030)

23.7. Market Revenue, by Service (2017–2030)

23.8. Market Volume, by End User (2017–2030)

23.9. Market Revenue, by End User (2017–2030)

Chapter 24. Brazil Market

24.1. Overview

24.2. Market Volume, by Phase (2017–2030)

24.3. Market Revenue, by Phase (2017–2030)

24.4. Market Volume, by Therapeutic Application (2017–2030)

24.5. Market Revenue, by Therapeutic Application (2017–2030)

24.6. Market Volume, by Service (2017–2030)

24.7. Market Revenue, by Service (2017–2030)

24.8. Market Volume, by End User (2017–2030)

24.9. Market Revenue, by End User (2017–2030)

Chapter 25. Mexico Market

25.1. Overview

25.2. Market Volume, by Phase (2017–2030)

25.3. Market Revenue, by Phase (2017–2030)

25.4. Market Volume, by Therapeutic Application (2017–2030)

25.5. Market Revenue, by Therapeutic Application (2017–2030)

25.6. Market Volume, by Service (2017–2030)

25.7. Market Revenue, by Service (2017–2030)

25.8. Market Volume, by End User (2017–2030)

25.9. Market Revenue, by End User (2017–2030)

Chapter 26. Saudi Arabia Market

26.1. Overview

26.2. Market Volume, by Phase (2017–2030)

26.3. Market Revenue, by Phase (2017–2030)

26.4. Market Volume, by Therapeutic Application (2017–2030)

26.5. Market Revenue, by Therapeutic Application (2017–2030)

26.6. Market Volume, by Service (2017–2030)

26.7. Market Revenue, by Service (2017–2030)

26.8. Market Volume, by End User (2017–2030)

26.9. Market Revenue, by End User (2017–2030)

Chapter 27. South Africa Market

27.1. Overview

27.2. Market Volume, by Phase (2017–2030)

27.3. Market Revenue, by Phase (2017–2030)

27.4. Market Volume, by Therapeutic Application (2017–2030)

27.5. Market Revenue, by Therapeutic Application (2017–2030)

27.6. Market Volume, by Service (2017–2030)

27.7. Market Revenue, by Service (2017–2030)

27.8. Market Volume, by End User (2017–2030)

27.9. Market Revenue, by End User (2017–2030)

Chapter 28. U.A.E. Market

28.1. Overview

28.2. Market Volume, by Phase (2017–2030)

28.3. Market Revenue, by Phase (2017–2030)

28.4. Market Volume, by Therapeutic Application (2017–2030)

28.5. Market Revenue, by Therapeutic Application (2017–2030)

28.6. Market Volume, by Service (2017–2030)

28.7. Market Revenue, by Service (2017–2030)

28.8. Market Volume, by End User (2017–2030)

28.9. Market Revenue, by End User (2017–2030)

Chapter 29. Competitive Landscape

29.1. List of Market Players and their Offerings

29.2. Competitive Benchmarking of Key Players

29.3. Product Benchmarking of Key Players

29.4. Recent Strategic Developments

Chapter 30. Company Profiles

30.1. Thermo Fisher Scientific Inc.

30.1.1. Business overview

30.1.2. Product and service offerings

30.1.3. Key financial summary

30.2. Marken

30.2.1. Business overview

30.2.2. Product and service offerings

30.2.3. Key financial summary

30.3. Catalent Inc.

30.3.1. Business overview

30.3.2. Product and service offerings

30.3.3. Key financial summary

30.4. Parexel International

30.4.1. Business overview

30.4.2. Product and service offerings

30.4.3. Key financial summary

30.5. Almac Group Limited

30.5.1. Business overview

30.5.2. Product and service offerings

30.5.3. Key financial summary

30.6. Biocair International Limited

30.6.1. Business overview

30.6.2. Product and service offerings

30.6.3. Key financial summary

30.7. Sharp Services LLC

30.7.1. Business overview

30.7.2. Product and service offerings

30.7.3. Key financial summary

30.8. Movianto International BV

30.8.1. Business overview

30.8.2. Product and service offerings

30.8.3. Key financial summary

30.9. PCI Pharma Services

30.9.1. Business overview

30.9.2. Product and service offerings

30.9.3. Key financial summary

30.10. Eurofins Scientific

30.10.1. Business overview

30.10.2. Product and service offerings

30.10.3. Key financial summary

Chapter 31. Appendix

31.1. Abbreviations

31.2. Sources and References

31.3. Related Reports



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 臨床試験用品の世界市場：産業分析・成長予測（～2030）]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 金属加工の世界市場：産業分析・成長予測（～2030）
  • 配電ユニットの世界市場：産業分析・成長予測（～2030）
  • 臨床試験バイオリポジトリー・アーカイブソリューションの世界市場：産業分析・成長予測（～2030）
  • シングルユースアセンブリの世界市場：産業分析・成長予測（～2030）
  • 加速度計医療センサーの世界市場：産業分析・成長予測（～2030）

    • ◆H&Iグローバルリサーチのお客様（例）◆